or Try an Advanced Search...

    Technical Analysis for ZLAB - Zai Lab Limited

    Grade Last Price % Change Price Change
    C 26.23 0.31% 0.08
    ZLAB closed up 0.31 percent on Wednesday, November 20, 2024, on 1.44 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical ZLAB trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    MACD Bearish Centerline Cross Bearish 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish 0.31%
    NR7 Range Contraction 0.31%
    Lower Bollinger Band Walk Weakness 0.31%
    Inside Day Range Contraction 0.31%
    Older End-of-Day Signals for ZLAB ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Support about 22 hours ago
    Rose Above 50 DMA about 22 hours ago
    Up 1% about 22 hours ago
    Possible NR7 1 day ago
    Possible Inside Day 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ZLAB Chart by TradingView
    Basic chart:

    Profile

    Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases

    Is ZLAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
    Nov 15 Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report
    Nov 15 Zai Lab Announces Pricing of Public Offering of American Depositary Shares
    Nov 14 Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations
    Nov 13 Zai Lab announces proposed public offering of American Depositary Shares
    Nov 13 Zai Lab Announces Proposed Public Offering of American Depositary Shares
    Nov 13 Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability
    Nov 12 Earnings Scheduled For November 12, 2024
    Nov 11 Zai Lab Q3 2024 Earnings Preview
    Nov 11 Zai Lab gets expanded Chinese approval for Vyvgart Hytrulo
    See more ZLAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 36.6
    52 Week Low 13.48
    Average Volume 920,526
    200-Day Moving Average 20.21
    50-Day Moving Average 26.38
    20-Day Moving Average 29.79
    10-Day Moving Average 28.27
    Average True Range 1.79
    RSI (14) 42.53
    ADX 32.21
    +DI 24.64
    -DI 33.93
    Chandelier Exit (Long, 3 ATRs) 31.24
    Chandelier Exit (Short, 3 ATRs) 30.24
    Upper Bollinger Bands 34.30
    Lower Bollinger Band 25.29
    Percent B (%b) 0.1
    BandWidth 30.24
    MACD Line -0.12
    MACD Signal Line 0.71
    MACD Histogram -0.8302
    Fundamentals Value
    Market Cap 2.59 Billion
    Num Shares 98.7 Million
    EPS -3.10
    Price-to-Earnings (P/E) Ratio -8.46
    Price-to-Sales 7.25
    Price-to-Book 2.09
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 27.87
    Resistance 3 (R3) 27.86 27.29 27.60
    Resistance 2 (R2) 27.29 26.87 27.30 27.51
    Resistance 1 (R1) 26.76 26.61 26.48 26.78 27.42
    Pivot Point 26.20 26.20 26.05 26.20 26.20
    Support 1 (S1) 25.67 25.78 25.38 25.68 25.04
    Support 2 (S2) 25.10 25.52 25.11 24.95
    Support 3 (S3) 24.57 25.10 24.86
    Support 4 (S4) 24.59